Cvijic Christine Mikail 4

What Happened

• Christine Mikail Cvijic, President, Chief Financial Officer and a director of Neurogene Inc. (NGNE), sold a total of 4,800 shares in open-market transactions: 600 shares on 2026-07-06 at a weighted average price of $36.02 for $21,613, and 4,200 shares on 2026-07-07 at a weighted average price of $36.13 for $151,763. Total proceeds were approximately $173,376.
• These were sales (not purchases) executed under a pre-established Rule 10b5-1 plan, so they are generally routine and scheduled rather than ad hoc insider trades.

Key Details

• Transaction dates and prices:
  • 2026-07-06: 600 shares at a weighted avg $36.02 (range reported $36.00–$36.035).
  • 2026-07-07: 4,200 shares at a weighted avg $36.13 (range reported $36.00–$36.455).
• Shares owned after the transaction:
  • The filing notes Cvijic no longer holds any shares jointly with her spouse following these sales.
  • She retains unvested restricted stock units totaling 46,168 RSUs (10,635 vests 3/13/2027; 13,533 vest in equal installments on 3/26/2027 & 3/26/2028; 22,000 vest annually on 2/20/2027–2/20/2029).
• Notable footnotes:
  • Sales were effected pursuant to a 10b5-1 trading plan adopted August 18, 2025 (F1).
  • Reported prices are weighted averages; the filer can provide a breakdown of the number of shares sold at each specific price within the disclosed ranges (F2, F4).
• Timeliness: Report filed 2026-07-07 for transactions on 2026-07-06 and 2026-07-07 — consistent with standard Form 4 timing (not indicated as late).

Context

• Sales made under a 10b5-1 plan are typically prearranged and do not necessarily reflect the insider’s current view of the company. For retail investors, purchases by insiders tend to carry more informational weight than routine sales; these transactions appear to be scheduled disposals of jointly held shares.